VivoSeq
Oncology

Colorectal Carcinoma

88

Pipeline Programs↗

15

Active Trials↗

37

Companies Involved↗

Colorectal Carcinoma is a moderately active landscape with 88 programs across 37 companies. The most active players are Jennerex Biotherapeutics, Lixte Biotechnology Holdings, Inc., Glaxo Dba Glaxosmithkline. 7 therapies are approved with 20 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

30/100

Mech. Concentration

9/100

Completion Rate

77/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Jennerex Biotherapeutics

2 programs

Phase 1L

Lixte Biotechnology Holdings, Inc.

1 program

Phase 1G

Glaxo Dba Glaxosmithkline

2 programs

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2B

Bexion Pharmaceuticals, Inc.

1 program

Phase 2I

Immatics Biotechnologies GmbH

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical6

Ipilimumab

Bristol-Myers Squibb

Zaltrap

Azienda U.S.L. 1 di Massa e Carrara

Cetuximab

Imclone

Mitomycin

UroGen Pharma Ltd.

Capecitabine and Oxaliplatin

Fudan University

Phase 16

Fruquintinib

Takeda

Ramucirumab

Eli Lilly

LB-100

Lixte Biotechnology Holdings, Inc.

MGD007

MacroGenics

JX-594

Jennerex Biotherapeutics

Phase 249

Vemurafenib

Conrado Roberto Hoffmann Filho

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Oxaliplatin

Teva

Dostarlimab

Glaxo Dba Glaxosmithkline

Fluorouracil

Elorac, Inc.

Phase 320

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Polyethylene Glycol 3350

AstraZeneca

Pembrolizumab

Merck & Co.

Bevacizumab

Bio-Thera Solutions

Approved7

Regorafenib

Bayer

Tucatinib

Pfizer

Abemaciclib

Eli Lilly

Metformin

EMD Serono

Axitinib

Prism Pharmaceuticals

Analysis

Modality Breakdown

75%

Small molecule

69 of 92 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody2123%RNA therapy11%Vaccine11%

Small molecule leads; the ring shows all 92 classified programs, each share of the total. Modality classified for 97% of 103 pipeline programs.

Analysis

Trial Status

72

clinical trials

Completed36 · 50%
Unknown status10 · 14%
Terminated8 · 11%
Recruiting7 · 10%
Enrolling by invitation3 · 4%
Not yet recruiting3 · 4%
Other5 · 7%

Clinical Trials

Trial Activity

72 trials

Clinicopathological Value of p16 Expression in Colorectal Carcinoma
Recruiting·SSohag University·N/A·NCT07047482·50 enrolled
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Recruiting·HHonorHealth Research Institute·Phase 1/2·NCT07463599·126 enrolled
Efficacy and Tolerability of a Simethicone-containing Evacuating Solution for Colorectal Cancer Screening Colonoscopy: a Randomized Parallel Comparative Trial CLEAN+
Recruiting·FFundacion Clinic per a la Recerca Biomédica·Approved·NCT07696793·818 enrolled
Phase Ib Study With the Combination of LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients - The CoLBAt Trial
Recruiting·TThe Netherlands Cancer Institute·Phase 1·NCT06012734·37 enrolled
Pilot Randomized Controlled Trial Assessing the Impact of Protect Your Colon™ on Colorectal Cancer Screening Behaviors
Recruiting·CCedars-Sinai Medical Center·Preclinical·NCT05929820·184 enrolled
BILMOD: BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention
Recruiting·MMassachusetts General Hospital·Preclinical·NCT07162337·40 enrolled
PROACT: Promoting Follow-Up of Abnormal Colorectal Cancer Screening Tests Through Multilevel Interventions
Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT06822530·682 enrolled
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
Active, not recruiting·BBexion Pharmaceuticals, Inc.·Phase 1/2·NCT05322590·195 enrolled
Screening With Liquid Biopsies to Address Colorectal Cancer Inequities
Active, not recruiting·UUniversity of California, San Diego·Preclinical·NCT06929481·340 enrolled
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1/2·NCT06484153·25 enrolled
Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer (SCRIT): A Multicenter Phase III Randomized Controlled Trial
Not yet recruiting·SShandong Cancer Hospital and Institute·Phase 3·NCT07686640·180 enrolled
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
Not yet recruiting·GGuangdong Provincial People's Hospital·Phase 3·NCT07686796·148 enrolled
Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma
Enrolling by invitation·—·N/A·NCT07334587·248 enrolled
Optimizing Colorectal Cancer Screening Among Patients With Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches
Enrolling by invitation·RRutgers, The State University of New Jersey·Preclinical·NCT05785780·30 enrolled
Large-Scale Implementation of a Decision Aid About Colorectal Cancer Screening
Enrolling by invitation·IIndiana University·N/A·NCT06597955·400 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)